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Steroid hormone receptors and their clinical
significance in cancer
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Introduction
Although all cells within the body are exposed
to steroid hormones, their physiological actions
are limited to those tissues which contain in-
tracellular binding proteins, termed receptors.
These proteins specifically bind the individual
classes of steroid hormones with high affinity
and transmit the steroid signal to sensitive genes
located throughout the chromatin. The type of
response subsequently induced is dependent
on both the developmental stage and differ-
entiation status of the target tissue, but may
involve the control of such diverse end points
as cell proliferation, cell death, secretory ac-
tivity, and cellular mobility. Importantly, the
ability of steroid hormones to influence these
characteristics is retained in many disease
states, notably in certain cancers originating
in steroid hormone sensitive tissues including
carcinomas of the breast,' genital tract,23 gas-
trointestinaI tract,4 pancreas,5 lung,6 and also
intracranial tumours.7 This has been harnessed
therapeutically, with drugs which modify the
cellular levels or actions of steroid hormones
being commonly used in the treatment of
breast, endometrial and prostate cancer.89
These tumours frequently retain steroid hor-
mone receptors and their measurement is cur-
rently used diagnostically in several centres to
identify potential endocrine responsiveness.
As steroid sensitive cancers are relatively
common and as cellular transitions associated
with the loss of their hormone sensitivity in-
variably worsen the prognosis for a patient,
considerable effort has been afforded to their
study. The examination of steroid hormone
receptors is pivotal to our understanding of
endocrine sensitivity and therefore the current
article attempts to summarise our present
knowledge ofthese proteins specifically in those
areas of cancer biology which we hope are of
particular interest to the pathologist.
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Molecular aspects of steroid hormone
receptors
The past decade has seen a remarkable increase
in our knowledge of the structure and function
ofsteroid hormone receptors. This has occurred
through the isolation and sequence analysis of
recombinant DNA clones for the individual
receptors. It is now established that the receptor
proteins from each of the five classes of steroid
hormones, notably oestrogens (ER)'0 and
progestins (PR),'0 androgens (AR), gluco-
corticoids (GR)," 12 and mineralocorticoids, as
well as the receptors for thyroid hormone,"
1,25-dihydroxy vitamin D3 (VDR),'4 retinoids
(aE, ,B and y) and so called "orphan" receptors,'0
which do not have recognised physiological
ligands as yet (including HNF-4,'5 COUP,'6
Rev-erb A-alpha,'7 Nur77,'8 NGFI-B,'9 TR3,2.
retinoid X receptor,2' P-450 inducers,"
and the DHR3/MHR3 proteins22), show
marked conservation of structure and contain
various functional domains, including those for
ligand and DNA binding.2324 In each instance
the steroid receptors act as ligand inducible
nuclear transcription factors, with interactions
between activated receptors and hormone re-
sponse elements (HRE) on the DNA directly
modifying gene expression. 1 2125 Although
some differences exist with respect to the or-
ganisation and initial cellular localisation of
the individual classes of steroid hormone recep-
tors, 2 they all ultimately act to stimulate or
repress mRNA production from sensitive
genes, leading to changes in protein synthesis
and finally cellular function.23-25 However, it
has become increasingly evident that steroid
hormone receptors represent only part of the
transcriptional apparatus involved in the
regulation ofresponsive genes and that they act
in concert with other inducers or suppressors of
gene expression. 10 26 Thus, hormonally directed
genes can show responsiveness to peptide
growth factors. This is exemplified by the oes-
trogen regulated gene pS2 (pNR2) which has
been shown to be sensitive to the growth factors
transforming growth factor cz (TGFoc), epi-
dermal growth factor and also insulin-like
growth factor I.27 A further example is seen
with PR, traditionally an oestrogen regulated
protein, which can also be activated through
dopaminergic and adrenergic signalling mech-
anisms.28 Such interactions raise interesting
questions concerning the role of cross-talk be-
tween steroid hormone receptors and other
signalling pathways in the regulation of tran-
scriptional efficiency, constitutive action of the
receptor and acquisition of endocrine re-
sistance. A knowledge of such pathways may
provide previously unrecognised opportunities
for tumour therapy.'°
Methods of detection
The observation that hormone sensitive tissues
were able to take up and retain radiolabelled
steroids against a concentration gradient of the
steroid26 lead to the initial discovery of steroid
hormone receptors. This property was sub-
sequently exploited in "test tube" biochemical
assays, notably dextran coated charcoal (DCC)
adsorption ligand binding assays (LBA' 26),
generating information on the concentration of
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steroid hormone receptors within solubilised
tissue extracts, together with their binding
affinity constants. Unfortunately, the ease of
performing these assays and also their sub-
sequent clinical value varies between tumour
types and surgical procedures used. Thus, while
breast and endometrial cancer samples are rel-
atively accessible enabling valuable data to be
readily obtained, it is often essential to remove
prostate tumour specimens by transurethral
sectioning, a procedure which generates el-
evated temperatures and consequently is po-
tentially damaging to any receptor proteins.26
Furthermore, the assays are also influenced by
both the cellularity of the cancer and the con-
tent and associated steroid hormone receptor
status ofnormal or benign tissue. These factors
may contribute towards falsely negative or
positive receptor results.
More recently developed methodologies rely
on direct antigen recognition rather than ster-
oid binding activity, utilising monoclonal
antibodies29 specific for the various steroid re-
ceptors in both enzyme immunoassays (for ex-
ample, oestrogen receptor enzyme immuno-
assay (ER-EIA)"0) and also immunocyto-
chemistry (for example, oestrogen receptor
immunocytochemical assay (ER-ICA) 26 31).
The value of the latter technique lies in its
relevance to histological sections and thus the
procedure has numerous advantages for the
pathologist. Steroid receptors can be directly
visualised by a colour reaction within individual
cell types. This is not possible using bio-
chemical methods, which require that tissues
should be homogenised before being assayed,
with an associated loss ofinformation regarding
heterogeneity of receptor expression in normal,
benign and malignant components of the
tumour.26 Immunohistochemical assays can
also be applied to biopsied or cytological ma-
terial' and thus have the ability to generate
accurate results on low cellular tumours. Fur-
thermore, the technique allows several different
proteins to be investigated on the multiple
sections obtained from each tissue sample,
readily permitting the construction of a larger
biological profile of the tumour. Scoring of
nuclear heterogeneity after immunocyto-
chemical staining is possible either manually
or using an image analyzer, both methodologies
correlating with each other when carried out
by experienced workers.32 Manual assessment
involves the construction of a H score" which
takes into account both the percentage pos-
itivity and staining intensity, while image anal-
yzers can be used to assess the percentage
of nuclear area immunopositivity."2 In breast
cancers the use of cut off values32 aids the
examination of relations between the degree
of ER/PR immunostaining and response to
endocrine therapies.'4 Intra- and inter-
laboratory studies35 monitoring immuno-
cytochemical performance and also external
quality assurance (QA) schemes for steroid
hormone receptor immunocytochemistry are
finally emerging. The UK Steroid Receptor
Quality Assessment Group has recently been
established, spear-headed by Dr R Leake (De-
partment of Biochemistry, University of
Glasgow), providing new workers with vital
information regarding steroid receptor QA
materials, QA schemes as well as a reference
directory of expert laboratories currently en-
gaged in such assays.
Early immunocytochemical studies using
antibodies directed against ER (for example,
H222 antibody, available in the ER-ICA kit"
from Abbott Diagnostics, North Chicago, Il-
linois, USA) showed that the protein is localised
exclusively within the epithelial cell nuclei in
suitably fixed cryosections" (that is, frozen
specimens stored at - 700C, sectioned and
fixed for 10 to 15 minutes in 3-7% form-
aldehyde/phosphate buffered saline at room
temperature; post-fixed in methanol (five min-
utes) and acetone (three minutes) at - 200C)
of normal and cancerous genital tract, breast,
pituitary, and liver. This observation was at
odds with the previously held view of this re-
ceptor as a cytosolic protein which was sub-
sequently translocated to the nucleus following
its activation by oestrogens. It is now believed
that, with the exception of glucocorticoid re-
ceptors, each class of steroid hormone receptor
resides predominantly in the nuclei of steroid
sensitive cells.'
Using such antibodies, ER (H222 and 1D5
(Dako, High Wycombe, UK)) and PR may
now also be reliably localised in 10% buffered
formalin fixed (exposed to formalin for no
longer than 24 hours as prolonged fixation
results both in decreased receptor immuno-
reactivity and in the appearance of non-specific
cytoplasmic staining), paraffin wax embedded
material following the re-exposure of masked
antigenic determinants by controlled protease
digestion of the tissue sections'6 or microwave
treatment.'7 These procedures maintain ex-
cellent tissue preservation, and thus accurate
receptor determinations can be made in the
invasive component of archival tumours, as
well as within small, early cancers which are
usually processed entirely as formalin fixed,
paraffin wax embedded material.
The cloning of the steroid receptor genes
and the generation of specific cDNA and oligo-
nucleotide probes has allowed northern hy-
bridisation analysis to be applied to tumour
extracts. However, this procedure, while semi-
quantifiable, is subject to many of the prob-
lems described for steroid receptor biochemical
assays which utilise tumour lysates. For-
tunately, several groups have begun to use in
situ hybridisation technologies to study hor-
mone receptor mRNA levels in histological
sections. Indeed, both isotopic and non-iso-
topic (notably digoxigenin) probe labelling pro-
cedures can now be used successfully to study
the cellular expression of steroid receptor
mRNA within frozen and paraffin wax em-
bedded tumour material.'839 Although in situ
hybridisation is often less amenable to routine
use than immunohistochemistry, a recent
study'8 has illustrated its potential value in
understanding defects in the steroid receptor
transcription/translation pathway. The ex-
quisite sensitivity of this technique has revealed
that more mRNA positive results can be re-
corded for ER than for the resultant protein,38
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implying significant post-transcriptional re-
gulation ofER mRNA, assuming that any neg-
ativity recorded for the receptor protein is
genuine and not merely the result of poor assay
sensitivity.
Steroid hormone receptor expression in
the breast
Steroid hormones, notably oestrogens, are of
central importance in growth regulation of the
breast.40 This requirement is often maintained
in the various disease states, including neo-
plasia. Receptors for the steroid hormones
oestrogen and progesterone can thus be
demonstrated immunocytochemically in the
normal mammary luminal epithelium, but
staining is usually sparse (7% of cells) and
largely confined to the lobular elements in the
premenopausal breast."'4 This is paradoxical
as the mammary parenchyma is usually re-
garded as exquisitely steroid hormone sensitive,
suggesting that such ER negativity should per-
haps be viewed with caution. It may merely
represent the limits of detection of the assay
used or may indicate cellular quiescence.4'42
ER concentrations in the breast are suppressed
at ovulation when there is a surge of oestrogens
in premenopausal women so that the ER con-
centrations are lowest during the luteal phase.'
This sharply contrasts with PR, which is under
regulation by both oestrogen and progesterone
and is relatively constant throughout the
cycle.4344
Steroid hormone receptors are largely main-
tained in benign breast conditions, ''45 while
elevated expression is often associated with
breast neoplasia.'26 Heterogeneity of ex-
pression is marked both between patients and
within an individual tumour.'26 Approximately
70% of primary breast cancers are ER positive
while 50% are PR positive, and the proportion
of ER positive tumours increases with age.' 42
ER positive tumours are more likely to spread
to bone, while ER negative tumours often
metastasise to the liver, brain and regional
lymph nodes.' 46 The measurement of ER and
PR concentrations in breast cancer specimens
is of therapeutic value, providing a means of
preselecting patients for various endocrine
treatments (primarily antioestrogens), with
approximately 75% of advanced breast cancer
patients with tumours positive for ER and PR
achieving favourable clinical remission.'2647
This compares with only 5-10% of patients
with steroid receptor negative disease showing
an objective response.26 Tumours containing
higher steroid receptor concentrations are more
likely to respond than those with reduced
concentrations. 26 PR has been reported to be
an independent predictive factor for response
to the antioestrogen tamoxifen48 and the pre-
dictability of response is reported to be in-
creased to 90% by measuring in vivo induction
of this receptor resultant from the partial ag-
onistic activity shown by tamoxifen acting via
an intact ER mechanism.49 Such receptor as-
says also provide prognostically useful in-
formation. The presence of ER has been
correlated with a series offavourable prognostic
characteristics, including a well differentiated
histology, low nuclear grade, low cellular pro-
liferation, prominent elastosis, slight or absent
lymphocytic infiltration, and minimal tumour
necrosis.'26 For the first five to 10 years after
primary surgery, patients with ER rich tumours
have a more favourable prognosis that those
with receptor negative disease.2650 Un-
fortunately, however, with a longer follow up
time and in the absence of adjuvant endocrine
treatment, the disease free intervals converge.'
In adjuvant endocrine trials greatest benefit is
predictably observed in those women with ER/
PR rich cancers.'26 51
In the UK the use of these assays to tailor
therapy to the tumour characteristics of in-
dividual patients is only sparingly applied and
a more pragmatic approach is frequently un-
dertaken which uses the relatively non-toxic
antioestrogenic drug tamoxifen to assess en-
docrine responsiveness clinically.42 This ap-
proach has arisen primarily from inaccuracies
observed in the prediction of clinical response
by steroid receptor assessment.52 An im-
munohistochemical approach to steroid hor-
mone receptor measurements, however,
facilitates the construction of a broader bio-
logical view of the tumour and demonstrates
that further elements other than steroid re-
ceptors can influence and correlate closely with
clinical response to endocrine treatments.
Thus, the increased expression of various pep-
tide growth factors (notably TGFc(53) and their
receptors (EGFR5455), proto-oncogene prod-
ucts (c-erbB254) and also markers indicative of
cell proliferative activity (Ki6754) have been
associated with loss of endocrine sensitivity40
despite positivity for steroid receptors often
being maintained.
It is also possible that further anomalies could
arise in the prediction of clinical response to
endocrine therapy using steroid receptor pro-
files if these receptors were occasionally non-
functional. An interesting approach to the iden-
tification of functionality of steroid receptors
has been to measure their gene products. It is
fair to say, however, that the identification of
target genes involved in the hormonal control
of cell behaviour has lagged behind the analysis
of the structure and function of these receptors
as transcription factors. Most progress has been
made with oestrogen regulated genes, with sev-
eral groups reporting successful cloning strat-
egies. PR52, pS256, pLIV1,57 and cathepsin D58
have been described as oestrogen regulated
proteins, with all but cathepsin D showing
enrichment within ER positive disease.565759
Where studied, the expression of oestrogen
regulated gene products in clinical breast can-
cer, although often associated with endocrine
responsiveness and invariably also having prog-
nostic value,56 does not add substantially to
the information that may be gained from ER
measurements alone. Where the expression of
several oestrogen regulated genes has been
studied within the breast cancer population, it
is evident that they are not always co-expressed
in ER positive disease. Their differential ex-
pression may reflect differing biological be-
haviour patterns of the tumours, with-for
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example, ER/pLIVl dual positivity significantly
correlating with lymph node involvement in
contrast to ER/pS2 positivity.60
Potentially, the control of such activities may
reside in variations in the promoters of in-
dividual genes or in the sensitivity of the pro-
moters to mutations in the ER. Possibly the
most important value of polymerase chain re-
action (PCR) amplification technology in
steroid receptor determination is the highly
sensitive detection of rare defects in the steroid
receptor genes and their mRNAs.61 An ex-
panding number of ER mutations have now
been documented, including those which can
lead to either a loss of either the hormone or
DNA binding domain. Several mutations have
been successfully identified, albeit at a low
frequency, in human breast cancers in vivo.6263
These frequently occur through frame shift/
termination mutations in the ER gene, gen-
erating what has been appropriately described
by the group from Texas as "outlaw re-
ceptors".62 The functional significance of these
mutants has been demonstrated by Fuqua et
a164 who showed that ER lacking exon 5, en-
coding the hormone binding domain, con-
stitutively activated transcription of a normally
oestrogen dependent gene construct in yeast
cells. These observations show that a mutant
ER could potentially dramatically affect oes-
trogen responsiveness of a cancer by acting as
a constitutive activator of gene expression even
in the absence of oestrogens,62 and thus such
mutations could potentially be ofsome import-
ance in controlling breast cancer growth ob-
served following the acquisition of hormone/
antihormone resistance.63 Similarly, mutations
in the DNA binding domain could alter the
DNA specificity of the receptor leading to pro-
miscuous activation of genes not normally re-
sponsive to oestrogens, or result in the loss
of DNA binding. Most striking is the recent
observation showing that ER variants can in-
terfere with the function of the wild-type
receptor,62 64 either by forming inactive
heterodimer complexes or by binding to the
oestrogen response element (ERE) in a re-
dundant conformation. These observations
suggest that mutations can act in a rather in-
sidious way as dominant negative oncogenes.62
Steroid hormone receptor expression in
the female genital tract
The female genital system, like the breast, is a
prime target organ for the steroid hormones
progesterone and oestrogen. Steroid receptors
are present throughout the reproductive tract
in the ovaries, endometrium, cervix, and vulva.2
Steroid hormone dependence is particularly
marked in the endometrium, which in the pre-
menopausal woman contains glandular epi-
thelial cells (and to a lesser extent stroma)
with both ER and PR.26' In common with the
normal breast, receptors in the endometrium
vary noticeably in concentration with the fluc-
tuations that occur in their respective ligands
throughout the menstrual cycle.265 Thus, ER
peaks in the proliferative phase of the cycle
when the circulating concentrations of pro-
gesterone are low, and subsequently falls under
the inhibition of rising progesterone during
the secretory phase. PR is induced during the
proliferative phase by elevated oestrogen con-
centrations.
As in the breast, steroid hormone receptors
are maintained in the female reproductive tract
during the process of neoplasia.2 Similarly,
there is a loss of these receptors in the genital
tumour epithelial cells with diminished
tumour differentiation and advancement of
malignancy.26667 Thus, in the endometrium,
PR (and to a lesser extent ER) concentrations
are inversely related to tumour grade and stage,
while they are usually diminished in associated
metastases.2266667
Although not of established value as yet,
steroid receptor analyses look promising for the
stratification of endometrial cancer patients for
endocrine therapy (primarily progestational
agents26). Thus, PR is proving to be a par-
ticularly valuable index ofresponse to progestin
therapy in such tumours. There is an overall
response rate of89% for PR positive metastatic
endometrial adenocarcinomas compared with
only 17% for receptor negative cancers.26 Un-
fortunately, the therapeutic usefulness of ER
is thought to be more limited.226 Indeed, in
ovarian cancers the concentrations of ER re-
ported are on average lower than those recorded
in breast cancers,2 and this may explain the
overall poor and often conflicting objective re-
sponse rate of ovarian cancer to antioestrogen
therapy.
The assessment of steroid receptors is also
potentially of important prognostic value in
female genital cancers.2 This is most apparent
for endometrial cancer, where PR positivity is
associated with an increased disease free in-
terval and improved survival.68 The usefulness
of ER assessment in genital cancers is again
more controversial,2 26 6 although dual as-
sessment of a high tumour ER and PR content
is, however, usually an indicator of longer
survival.7071
Steroid hormone receptor expression in
the male genital tract
It is known that as with the female, the male
reproductive system is also under strict steroid
hormone control in both normal and disease
states. Thus, the prostate gland contains re-
ceptors for androgens (AR) in its secretory
epithelia.72 In contrast to the breast, however,
there have been difficulties in the development
of accurate biochemical and immunocyto-
chemical assays for prostatic AR,26 although
research in this field is now expanding rapidly
as antibodies to the receptor become more
readily available.7' The steroid receptors ER
and PR have also been identified in the uro-
thelium of the central prostatic ducts and the
prostatic urethra, in the periglandular fibro-
cytes, smooth muscle cells, interglandular
stromal cells, and also associated with the
stroma surrounding the ejaculatory ducts and
seminal vesicles, although the secretory epi-
thelia are thought to be ER and PR negative.74
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All three of these steroid hormone receptors3
have been shown to be more apparent in benign
prostatic hyperplasia (BPH), while AR con-
centrations are usually reduced in carcinomas
compared with those seen in BPH,73 with an
inverse correlation existing between receptor
expression and grade.5 While the ER and the
PR status are of some predictive value in many
neoplasms of the female reproductive system
and the breast, it is the AR that is of primary
importance in prostate carcinoma. Indeed, this
forms the rationale for treatment of the disease
with antiandrogenic drugs and AR positive tu-
mours usually have a better response to such
therapies.26 Recent data suggest that the scoring
of AR immunostaining intensity rather than
percentage positivity" may possibly dis-
criminate good responders.
As seen with ER in the breast, a number of
AR mutations have been detected in clinical
prostate cancer specimens7778 and also within
the LNCaP prostate carcinoma cell line.79 Im-
portantly, the AR mutation in LNCaP cells
greatly influences the specificity of hormone
binding, resulting in receptors that have an
increased binding affinity for both oestradiol
and progesterone, with the antiandrogen
hydroxyflutamide acting as an agonist.79 In-
terestingly, Schoenberg et a175 have identified a
mutation in the AR gene in some patients with
prostate cancer who also exhibit an agonistic
response to flutamide. These data suggest that
a knowledge of mutations may be critical in
determining appropriate methods of treatment
with steroid hormones or antagonists.79 In clin-
ical materialAR mutations are thought to occur
as late events and are thus quite prevalent in
advanced disease where they have been linked
with the acquisition of androgen insensitivity.77
Conclusions
It is apparent that steroid hormone receptors
are of pivotal importance in the control of
growth and development of steroid hormone
sensitive tissues in their normal and disease
states. This has been harnessed therapeutically,
with antihormonal drugs, which bind to these
receptors thereby competing with endogenous
steroid hormones, frequently being used in the
treatment of breast, endometrial and prostate
cancer. The measurement of steroid receptors
is now used in many centres to stratify such
patients for the potential hormonal/anti-
hormonal responsiveness oftheir tumours. This
is exemplified in breast cancer, where ER and
PR are monitored, but is also of growing
importance in genital cancers in both women(PR) and men (AR). It is becoming increasingly
obvious that a wider knowledge of the mol-
ecular and cellular biology of these receptors
in their functional and non-functional forms
is an essential prerequisite to the full under-
standing of pathways of steroid hormone
sensitivity and insensitivity. Much of this work
could be performed by the pathologist,80 with
clinical material representing the final testing
ground for experimentally derived hypotheses.
It is envisaged that involvement of the path-
ologist in monitoring steroid hormone re-
ceptors would ultimately provide data that
might be used to aid in selecting primary or
adjuvant therapy, evaluating new therapies, es-
timating prognosis, and assessing outcome.80
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